Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci

Nikolaos A Patsopoulos, Federica Esposito, Joachim Reischl, Stephan Lehr, David Bauer, Jürgen Heubach, Rupert Sandbrink, Christoph Pohl, Gilles Edan, Ludwig D Kappos, David Miller, Javier Montalbán, Chris H. Polman, Mark S Freedman, Hans-Peter Hartung, Barry G.W. Arnason, Giancarlo Comi, Stuart Cook, Massimo Filippi, Douglas S. GoodinDouglas Jeffery, Paul O'Connor, George C. Ebers, Dawn Langdon, Anthony T. Reder, Anthony L. Traboulsee, Frauke Zipp, Sebastian Schimrigk, Jan Hillert, Melanie Bahlo, David R. Booth, Simon A Broadley, Matthew A. Brown, Brian L. Browning, Sharon R. Browning, Helmut Butzkueven, William MacEwan Carroll, Caron Chapman, Simon J Foote, Lyn Griffiths, Allan G. Kermode, Trevor J Kilpatrick, Jeanette Lechner-Scott, Mark Marriott, Deborah Mason, Pablo Moscato, Robert N. Heard, Michael P Pender, Victoria M Perreau, Devindri Perera, Justin P. Rubio, Rodney J Scott, Mark Slee, Jim Stankovich, Graeme J. Stewart, Bruce V. Taylor, Niall Tubridy, Ernest Willoughby, James Wiley, Paul Matthews, Filippo Martinelli-Boneschi, Alastair Compston, Jonathan L Haines, Stephen L Hauser, Jacob L McCauley, Adrian J Ivinson, Jorge R Oksenberg, Margaret A Pericak-Vance, Stephen J Sawcer, Philip Laurence De Jager, David A. Hafler, Paul I W de Bakker

Research output: Contribution to journalArticleResearchpeer-review

242 Citations (Scopus)

Abstract

Objective: To perform a 1-stage meta-analysis of genome-wide association studies (GWAS) of multiple sclerosis (MS) susceptibility and to explore functional consequences of new susceptibility loci. Methods: We synthesized 7 MS GWAS. Each data set was imputed using HapMap phase II, and a per single nucleotide polymorphism (SNP) meta-analysis was performed across the 7 data sets. We explored RNA expression data using a quantitative trait analysis in peripheral blood mononuclear cells (PBMCs) of 228 subjects with demyelinating disease. Results: We meta-analyzed 2,529,394 unique SNPs in 5,545 cases and 12,153 controls. We identified 3 novel susceptibility alleles: rs170934 T at 3p24.1 (odds ratio [OR], 1.17; p = 1.6 × 10-8) near EOMES, rs2150702G in the second intron of MLANA on chromosome 9p24.1 (OR, 1.16; p = 3.3 × 10-8), and rs6718520A in an intergenic region on chromosome 2p21, with THADA as the nearest flanking gene (OR, 1.17; p = 3.4 × 10-8). The 3 new loci do not have a strong cis effect on RNA expression in PBMCs. Ten other susceptibility loci had a suggestive p < 1 × 10-6, some of these loci have evidence of association in other inflammatory diseases (ie, IL12B, TAGAP, PLEK, and ZMIZ1). Interpretation: We have performed a meta-analysis of GWAS in MS that more than doubles the size of previous gene discovery efforts and highlights 3 novel MS susceptibility loci. These and additional loci with suggestive evidence of association are excellent candidates for further investigations to refine and validate their role in the genetic architecture of MS.

Original languageEnglish
Pages (from-to)897-912
Number of pages16
JournalAnnals of Neurology
Volume70
Issue number6
DOIs
Publication statusPublished - Dec 2011
Externally publishedYes

Cite this